Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release 89bio, Inc Announces Upsized Pricing Of $125 0 Million Public Offering Of Common Stock And Pre Funded Warrants is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
(2024-11-12 | NDAQ:ETNB) 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants Stockhouse.com uses cookies on this site. By continuing to use ... Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants 89bio, Inc. Tue, Nov 12, 2024, 11:58 PM 5 min read ... Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
--89 bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today ... Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ... Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
Detailed price information for 89Bio Inc (ETNB-Q) from The Globe and Mail including charting and trades. Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ... Read More
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering ...
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ... Read More
89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering ...
89Bio, Inc. Announces Upsized Pricing Of $125.0 Million Public Offering Of Common Stock And Pre-Funded Warrants ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus